INVESTIGATION OF VANCOMYCIN UTILIZATION PATTERNS  AT BUON MA THUOT MEDICAL UNIVERSITY HOSPITAL IN 2024

Vũ Thị Hồng Nhung; Hoàng Thị Thu Huyền; Hoàng Thúy Bình; Doãn Phương Linh; Nguyễn Hoàng Anh Thư; Cao Thu Hiền; Lê Trung Khoảng

doi:10.34238/tnu-jst.13019

INVESTIGATION OF VANCOMYCIN UTILIZATION PATTERNS AT BUON MA THUOT MEDICAL UNIVERSITY HOSPITAL IN 2024

About this article

Received: 09/06/25 Revised: 02/12/25 Published: 03/12/25

Authors

1. Vu Thi Hong Nhung, Buon Ma Thuot Medical University
2. Hoang Thi Thu Huyen, Buon Ma Thuot Medical University
3. Hoang Thuy Binh, Buon Ma Thuot Medical University
4. Doan Phuong Linh, Buon Ma Thuot Mecical University Hospital
5. Nguyen Hoang Anh Thu, Tay Nguyen University
6. Cao Thu Hien, Dak Lak Traditional Medicine Hospital
7. Le Trung Khoang , Buon Ma Thuot Medical University

Abstract

This study aimed to evaluate the utilization patterns of vancomycin for treatment at Buon Ma Thuot Medical University Hospital in 2024. Medical records of 85 patients, from January to December 2024, were analyzed using descriptive statistics to evaluate patient characteristics, the Chi-square test was applied to assess the association between red man syndrome and infusion rate. The mean patient age was 57.16 ± 18.26 years, with males slightly more common (51.76%). The median treatment duration was 7 (5–9) days. Primary indications included bone and joint infections (34.11%),most patients had a glomerular filtration rate >60 mL/min, and Staphylococcus aureus was the predominant pathogen. The most common dosing regimen was 1000 mg twice daily (70.59%), infusion rates ≥10 mg/min were recorded in 77.65% of cases. The red man syndrome occurred in 4/85 patients, no significant association was found between the incidence of red man syndrome and infusion rate (p>0.05). This study has characterized the patterns of vancomycin use. However, to further support clinical practice, prospective studies are needed to explore the relationship between dosing, plasma concentrations, and clinical outcomes to optimize treatment regimens for patients.

Keywords

Red man syndrome; Antibiotics; Inpatients; Drug utilization; Vancomycin

Full Text:

PDF (Tiếng Việt)

References

[1] Ministry of Health, Vietnamese National Drug Formulary. Ha Noi: Science and Technics Publishing House, (in Vietnamese), 2022.

[2] S. Patel, C. V. Preuss, and F. Bernice, "Vancomycin," in StatPearls, Treasure Island (FL): StatPearls Publishing, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK459263/. [Accessed May 5, 2025].

[3] V. M. Eichel et al., "Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis," J. Hosp. Infect., vol. 141, pp. 119-128, Nov. 2023, doi: 10.1016/j.jhin.2023.09.008.

[4] F. Iqbal et al., "Vancomycin-resistant enterococci: A rising challenge to global health," Clinical Epidemiology and Global Health, vol. 28, 2024, doi: 10.1016/j.cegh.2024.101663.

[5] S. Selim et al., "Incidence of Vancomycin-Resistant Staphylococcus aureus Strains among Patients with Urinary Tract Infections," Antibiotics, vol. 11, no. 3, pp. 1-8, 2022. [Online]. Available: https://www.mdpi.com/2079-6382/11/3/408. [Accessed May 5, 2025].

[6] L. Xi et al., "Age-Related Differences in Vancomycin-Associated Nephrotoxicity and Efficacy in Methicillin-Resistant Staphylococcus aureus Infection: A Comparative Study between Elderly and Adult Patients," Antibiotics, vol. 13, no. 4, pp. 1-13, 2024. [Online]. Available: https://www.mdpi.com/ 2079-6382/13/4/324. [Accessed May 4, 2025].

[7] M. N. Jeffres, "The Whole Price of Vancomycin: Toxicities, Troughs, and Time," Drugs, vol. 77, no. 11, pp. 1143-1154, 2017, doi: 10.1007/s40265-017-0764-7.

[8] L. Brunetti et al., "The risk of vancomycin toxicity in patients with liver impairment," Annals of Clinical Microbiology and Antimicrobials, vol. 19, no. 1, pp. 1-9, 2020, doi: 10.1186/s12941-020-00354-2.

[9] W. Zamoner, I. R. S. Prado, A. L. Balbi, and D. Ponce, "Vancomycin dosing, monitoring and toxicity: Critical review of the clinical practice," Clin. Exp. Pharmacol Physiol, vol. 46, no. 4, pp. 292-301, Apr 2019, doi: 10.1111/1440-1681.13066.

[10] T. M. Mac, T. H. Nguyen, D. C. Dinh, T. P. T. Le, T. T. T. Nguyen, and T. L. H. Nguyen, "Investigation of vancomycin use at 108 Military Central Hospital," (in Vietnamese), Journal of 108 - Clinical Medicine And Pharmacy, vol. 16, special issue of Scientific Conference on the 70th anniversary of 108 Military Central Hospital, pp. 49-58, 2021, doi: 10.52389/ydls.v16iDB4.1012.

[11] D. P. Nguyen and H. V. A. Nguyen, "Analysis the current sistuation of use at Nghe An Friendship General Hospital," (in Vietnamese), Vietnam Medical Journal, vol. 538, no. 1, pp. 59-63, 2024.

[12] M. J. Rybak et al., "Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists," Am J. Health Syst. Pharm., vol. 77, no. 11, pp. 835-864, 2020, doi: 10.1093/ajhp/zxaa036.

[13] World Health Organization (WHO), "The Asia-Pacific perspective: Redefining obesity and its treatment," 2020. [Online]. Available: https://iris.who.int/bitstream/handle/10665/206936/ 0957708211_eng.pdf?sequence=1&isAllowed=y. [Accessed May 4th, 2025].

[14] A. M. Masich et al., "Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock," Pharmacotherapy, vol. 40, no. 3, pp. 211-220, Mar 2020, doi: 10.1002/phar.2367.

[15] M. S. Assadoon, J. C. Pearson, D. W. Kubiak, M. P. Kovacevic, and B. W. Dionne, "Evaluation of Vancomycin Accumulation in Patients With Obesity," Open Forum Infect Dis., vol. 9, no. 10, Oct 2022, doi: 10.1093/ofid/ofac491.

[16] S. Y. Tong, J. S. Davis, E. Eichenberger, T. L. Holland, and V. G. Fowler Jr, "Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management," Clin. Microbiol. Rev., vol. 28, no. 3, pp. 603-661, Jul. 2015, doi: 10.1128/cmr.00134-14.

[17] B. H. Le, T. M. Hoang, and T. X. P. Dong, "Investigation of vancomycin usage in elderly patients at Friendship Hospital," (in Vietnamese), Vietnam Medical Journal, vol. 540, no. 2, pp. 328-333, 2024.

[18] F. Tabuchi et al., "Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus," J. Antibiot (Tokyo), vol. 70, no. 6, pp. 771-774, Jun 2017, doi: 10.1038/ja.2017.7.

[19] H. Mohammadi-Berenjestanaki, V. Khori, H. Shirzad-Aski, and E. A. Ghaemi, "In Vitro Synergistic Effect of Vancomycin and Some Antibacterial Agents Against Clinical Methicillin-Resistant and Sensitive Staphylococcus aureus Isolates," Microb Drug Resist, vol. 26, no. 3, pp. 218-226, Mar 2020, doi: 10.1089/mdr.2019.0003.

[20] Uptodate, "Suggested approach to parenteral vancomycin dosing in adults who are not receiving hemodialysis," 2025. [Online]. Available: https://www.uptodate.com/contents/image?imageKey =ID/60466. [Accessed May 4th, 2025].

[21] T. P. T. Le et al., "Evaluating vancomycin therapeutic drug monitoring in adult patients at108 Military Central Hospital," (in Vietnamese), Journal Of 108 - Clinical Medicine And Pharmacy, special issue of Hospital Pharmacy Conference 2021, pp. 43-55, 2021.

[22] E. J. Filippone, W. K. Kraft, and J. L. Farber, "The Nephrotoxicity of Vancomycin," Clin. Pharmacol Ther., vol. 102, no. 3, pp. 459-469, Sep 2017, doi: 10.1002/cpt.726.

DOI: https://doi.org/10.34238/tnu-jst.13019

Refbacks

There are currently no refbacks.



Remember me